Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement with biopharmaceutical company IMV to explore a preclinical research collaboration that could combine each company's immunotherapy technologies.
The goal of the collaboration is to perform preclinical research studies that evaluate the combination of Navidea's CD206-activated macrophage-targeting therapeutics with IMV's DPX-based immunotherapies. Both companies will jointly conduct the research throughout the duration of the study.
The companies believe the joint research could lead to new approaches to treating a variety of cancers.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
